Astra to Pay Daiichi Up to $6 Billion for New Cancer Drug

Bookmark
(Bloomberg) -- AstraZeneca Plc agreed to pay as much as $6 billion to buy into Daiichi Sankyo Co.’s promising medicine for lung and breast cancer, the drugmakers’ second potential blockbuster oncol...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.